CLINICAL_TRIALS
ClinicalTrials.gov record update
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical Trial
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05494060
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:29.424039+00:00
- Published At
- 2023-11-07T00:00:00+00:00
- Record Updated At
- 2023-11-07
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Carcinoma", "Gastrointestinal Diseases", "Stomach Cancer", "Gastroesophageal-junction Cancer", "Digestive System Diseases", "Gastric Cancer", "Gastrointestinal Neoplasms"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-11-07"- protocolSection.identificationModule.nctId
"NCT05494060"- protocolSection.identificationModule.officialTitle
"XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical Trial"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.